| Eligibility |
Inclusion Criteria:
- Pat centrally confirmed diagnosis of solitary fibrous tumor
- Expression of PDGFRB and/or VEGFR2 by immunohistochemistry on formalin fixed-paraffin
embedded (FFPE) material as minimal requirement. Activation of PDGFRB and/or VEGFR2 by
real time C reactive protein of PDGFB and VEGFA on FFPE material (if in sufficient
quantity) or by biochemistry on frozen material (if available)
- Locally advanced disease (i.e. surgical resection of local disease unfeasible
radically, or unaccepted by the patient, or amenable to become less demolitive, or
feasible, or easier, after cytoreduction) and/or metastatic disease
- Measurable disease
- Centrally confirmed evidence of progression by RECIST during the 6 months before study
entry
- 1st-line vs 3-rd-line
- Eastern Cooperative Oncology Group (ECOG) Performance Status = 0, 1, 2
- Adequate bone marrow function, defined as the following: absolute neutrophil count
(ANC) >1.5 x 109/L, platelets >100 x 109/L, Hb >9 g/dL. Blood transfusions are allowed
to reach the baseline requested Hb level
- Adequate organ function, defined as the following: total bilirubin within normal
institutional limits (but in case of Gilbert's syndrome), aspartate aminotransferase
(AST) and Serum Glutamic Pyruvic Transaminase (ALT) <2.5 x upper normal limit (UNL),
creatinine <1.5 x upper normal limit (UNL), within normal institutional limits or
creatinine clearance =60 mL/min/1.73 m2 for patients with creatinine levels above
institutional normal
- Cardiac ejection fraction =50% as measured by echocardiogram
- Age > 18 yrs
- Female patients of child-bearing potential must have negative pregnancy test within 7
days before initiation of study drug dosing. Post-menopausal women must be amenorrheic
for at least 12 months to be considered of non-childbearing potential. Male and female
patients of reproductive potential must agree to employ an effective method of birth
control throughout the study and for up to 3 months following discontinuation of study
drug
- No history of arterial and/or venous thromboembolic event within the previous 12
months
- Written, voluntary informed consent
Exclusion Criteria:
- Other primary malignancy with <5 years clinically assessed disease-free interval,
except basal cell skin cancer, cervical carcinoma in situ, or other neoplasms judged
to entail a low risk of relapse
- Previous treatment with any other investigational or not investigational agents and or
radiation therapy within 28 days of first day of study drug dosing, or patients who
have not recovered from adverse events due to agents administered more than 4 weeks
earlier
- Major surgery within 2 weeks prior to study entry
- Previous radiotherapy to =25 % of the bone marrow
- Concomitant other investigational agents or concurrent anticancer therapy. In
addition, all herbal (alternative) medicines are excluded
- Grade III/IV cardiac problems as defined by the New York Heart Association Criteria
(i.e., history of uncontrolled or symptomatic angina, history of arrhythmias requiring
medications, or clinically significant, with the exception of asymptomatic atrial
fibrillation requiring anticoagulation, myocardial infarction < 6 months from study
entry, uncontrolled or symptomatic congestive heart failure, ejection fraction below
the institutional normal limit)
- Known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis with
exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver
metastases or stable chronic liver disease per investigator assessment)
- Known diagnosis of human immunodeficiency virus (HIV) infection
- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to Axitinib
- Expected non-compliance to medical regimens
|
